Press releases
- Incyte to Present at Upcoming Investor Conference
- Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
- Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
- Incyte to Report First Quarter Financial Results
- Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
- Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
- Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
- New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
- Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AI
More ▼
Key statistics
On Thursday, Incyte Corp (ICY:DUS) closed at 49.66, 4.88% above its 52-week low of 47.35, set on Apr 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 49.15 |
---|---|
High | 49.66 |
Low | 49.15 |
Bid | 49.42 |
Offer | 49.57 |
Previous close | 47.97 |
Average volume | 54.20 |
---|---|
Shares outstanding | 224.53m |
Free float | 220.96m |
P/E (TTM) | 19.36 |
Market cap | 11.49bn USD |
EPS (TTM) | 2.64 USD |
Data delayed at least 15 minutes, as of May 02 2024 18:31 BST.
More ▼